To explore the potential of SCARA5 and AOX1 as epigenetic biomarkers we evaluated the methylation degree of each promoter CpG in NSCLC patients from the TCGA and CURELUNG NSCLC cohorts. The gene discussed is SCARA5; the disease is non-small cell lung carcinoma.